Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Genetic Disease

Search Medical Condition
Please enter condition
Please choose location from dropdown

Hemophilia Clinical Trials

A listing of Hemophilia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (111) clinical trials

Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies

Life expectancy of haemophilia patients (specially severe) has dramatically increase in the last decades, which lead to the apparition of aging diseases such as cardiovascular disease, with the potential bleeding risk of antiplatelet therapies and anticoagulants. The primary endpoint of the study is to evaluate this bleeding risk in haemophilia ...

Phase N/A

DDAVP vs. Exercise in Patients With Mild Hemophilia A

Persons with mild hemophilia A (MHA) (defined as having a FVIII level of >5% to 40%) bleed infrequently but can in the setting of trauma which can often is in the context of participating in sports/exercise. FVIII levels temporarily rise with stress, exercise and with DDAVP (1-desamino-8-D-arginine vasopressin, desmopressin). In ...

Phase

Swiss Hemophilia Registry

The Swiss Hemophilia Registry will collect data on the prophylactic and therapeutic use of factor concentrates in patients with hemophilia and other severe bleeding disorders in Switzerland.

Phase N/A

A Phase III Study on the Safety Pharmacokinetics and Efficacy of Coagulation Factor VIIa

A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Pediatric Patients from birth to <12 years old with Inhibitors to Factor VIII or IX: PerSept 2

Phase

Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients

The development of factor VIII inhibitors occurs in approximately 30 to 40% of patients with severe Haemophilia A. The main negative clinical and cost consequence is the ineffectiveness of replacement therapy in patients with high-titer antibodies, who have a shorter life and greater morbidity than those who do not develop ...

Phase

Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?

In the context of hemophilia, it is well know that the level of factor VIII alone does not reflect the clinical phenotype of the patients in an accurate way. At equal factor VIII levels, certain patients will bleed more than others. The thrombin generation test (TGT) is a test that ...

Phase N/A

Factor Product Utilization and Health Outcomes in Patients With Hemophilia

Recombinant factor VIII Fc (rFVIIIFc) and recombinant factor IX Fc (rFIXFc) are extended half-life coagulation factors approved by Health Canada in 2014 for the treatment of severe hemophilia A and B, respectively. The objectives of this observational study is to describe the change in annual factor consumption, clinical and patient-reported ...

Phase N/A

Individualizing Hemophilia Prophylaxis Using Thromboelastography

This is a pilot study in children and adults with severe hemophilia A that utilizes the TEG/ROTEM to personalize their prophylaxis treatment. Primary objectives: Assess the feasibility of TEG/ROTEM-guided modification of the current prophylaxis regimen for individuals with severe hemophilia A. Specifically, to: Test and refine the operational protocol for ...

Phase N/A

Efficacy and Safety of Shea Nut Oil in Hemophilic Arthropathy

Hemophilia is an X-linked recessive bleeding disorder caused by a deficiency of coagulation factor VIII (hemophilia A) or IX (hemophilia B). Severe hemophilia patients may have frequent spontaneous bleeding episodes such as joint and muscle bleeding. Repeated joint bleeding leads to chronic synovitis, cartilage damage and bony destruction, which is ...

Phase N/A

ADVATE Hemophilia A Outcome Database (AHEAD)

The purpose of the study is to document the natural history of hemophilia. A disease and long-term outcomes in terms of effectiveness, safety and quality of life (QoL) in participants receiving ADVATE in routine clinical practice. Participants may use any treatment regimen, including on-demand and prophylaxis using standardized regimens or ...

Phase N/A